SCHEMBL6986133

SCHEMBL6986133

CC1=CC(=NO)CC(c2cccc(Cl)c2)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
MCL1 Q07820 1/20 0.38
TRPM4 Q8TD43 1/20 0.37
TRPM5 Q9NZQ8 1/20 0.37
GRIN2B Q13224 2/20 0.36
MAPT P10636 3/20 0.35
HPGD P15428 2/20 0.35
ALDH1A1 P00352 1/20 0.35
TSHR P16473 1/20 0.35
EPAS1 Q99814 1/20 0.34
SLC6A3 Q01959 3/20 0.34
SLC6A2 P23975 2/20 0.34
SLC6A4 P31645 2/20 0.34
SLC9A1 P19634 2/20 0.33
IDO1 P14902 1/20 0.33
MAOA P21397 1/20 0.33
MAOB P27338 1/20 0.33
MAPK1 P28482 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7591386 1.00 HTT (0.38) HTTMEN1KMT2AMCL1TRPM4
SCHEMBL6978662 0.79 MAPT (0.43) HTTMEN1KMT2AMCL1MAPT
SCHEMBL6981391 0.79 MAPT (0.43) HTTMEN1KMT2AMCL1MAPT
SCHEMBL6985757 0.79 MAPT (0.43) HTTMEN1KMT2AMCL1MAPT
SCHEMBL7595212 0.70 MAPT (0.40) HTTMEN1KMT2AMCL1MAPT
SCHEMBL7595211 0.70 MAPT (0.40) HTTMEN1KMT2AMCL1MAPT
SCHEMBL27047585 0.70 TP53 (0.50) HTTMEN1KMT2AMCL1MAPT
SCHEMBL1072730 0.65 SLC6A3 (0.54) MEN1KMT2AMCL1MAPTSLC6A3
SCHEMBL8535215 0.61 MDM2 (0.48) HTTMEN1KMT2AMCL1MAPT
SCHEMBL8535211 0.61 MDM2 (0.48) HTTMEN1KMT2AMCL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1050530-B1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers SERVIER LAB (FR) 2003-10-22 EP disclosed
US-6451789-B1 CENTRAL NERVOUS SYSTEM DISORDERS; COGNITION ACTIVATORS LES LABORTOIRES SERVIER (FR) 2002-09-17 US disclosed
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes RAULT SYLVAIN (FR) 2002-04-11 US disclosed
US-6323222-B1 COGNITION ACTIVATORS, ALZHEIMER*S DISEASE AND ENZYME INHIBITORS ADIR ET COMPAGNIE (FR) 2001-11-27 US disclosed
EP-1050530-A1 1-Aza-2-alkyl-6-aryl-cycloalkanes usefull as memory enhancers ADIR ET COMPAGNIE (FR) 2000-11-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042413-A1 1-aza-2-alkyl-6-aryl-cycloalkanes SULT2A1, GRIN2A, NR3C1 HTT 446/4885MEN1 4318/4885KMT2A 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.